SM
Sabby Management Portfolio holdings
AUM
$13M
This Quarter Return
-0.14%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$143M
AUM Growth
+$143M
(-57%)
Cap. Flow
-$196M
Cap. Flow
% of AUM
-136.94%
Top 10 Holdings %
Top 10 Hldgs %
34.85%
Holding
254
New
32
Increased
29
Reduced
57
Closed
61
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$4.65M |
| 2 |
BIOA
BioAmber Inc.
BIOA
|
$3.39M |
| 3 |
OTIC
Otonomy, Inc.
OTIC
|
$3.29M |
| 4 |
BLRX
BioLineRX
BLRX
|
$3.02M |
| 5 |
United Therapeutics
UTHR
|
$2.35M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$59.7M |
| 2 |
Sarepta Therapeutics
SRPT
|
$55.3M |
| 3 |
Amgen
AMGN
|
$35.4M |
| 4 |
Eli Lilly
LLY
|
$15.7M |
| 5 |
Biogen
BIIB
|
$5.67M |
Sector Composition
| 1 | Healthcare | 83.28% |
| 2 | Materials | 3.26% |
| 3 | Consumer Staples | 0.47% |
| 4 | Consumer Discretionary | 0.4% |
| 5 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $13M | 0.7% | 239,180 -50,003 | -17% | -$2.72M |
|
|
2
Amgen
AMGN
$155B
| $6.09M | 0.33% | 37,104 -215,691 | -85% | -$35.4M |
|
3
Outlook Therapeutics
OTLK
$37.8M
| $6M | 0.32% | 2,238,470 | – | – |
|
|
4
Ionis Pharmaceuticals
IONS
$6.79B
| $4.65M | 0.25% | +115,694 | New | +$4.65M |
|
|
MTFB
5
DELISTED
Motif Bio plc ADRs
MTFB
| $4.6M | 0.25% | 755,875 -91,951 | -11% | -$560K |
|
|
OTIC
6
DELISTED
Otonomy, Inc.
OTIC
| $3.42M | 0.18% | 278,840 +268,840 | +2,688% | +$3.29M |
|
|
BIOA
7
DELISTED
BioAmber Inc.
BIOA
| $3.39M | 0.18% | +1,460,859 | New | +$3.39M |
|
|
BLRX
8
BioLineRX
BLRX
$16.2M
| $3.02M | 0.16% | +3,141,756 | New | +$3.02M |
|
9
Applied DNA Sciences
APDN
$1.69M
| $2.93M | 0.16% | 1,771,839 -337,762 | -16% | -$559K |
|
|
EIGR
10
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $2.74M | 0.15% | 238,907 -1,634 | -0.7% | -$18.7K |
|
11
Palisade Bio
PALI
$6.3M
| $2.72M | 0.15% | 515,216 +285,695 | +124% | +$1.51M |
|
|
SRRA
12
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $2.67M | 0.14% | 1,746,261 +805,420 | +86% | +$1.23M |
|
13
Indaptus Therapeutics
INDP
$7.19M
| $2.65M | 0.14% | 514,878 +778 | +0.2% | +$4.01K |
|
|
STML
14
DELISTED
Stemline Therapeutics, Inc.
STML
| $2.48M | 0.13% | 290,087 -67,719 | -19% | -$579K |
|
|
15
United Therapeutics
UTHR
$13.8B
| $2.35M | 0.13% | +17,342 | New | +$2.35M |
|
|
SCPX
16
DELISTED
Scorpius Holdings, Inc.
SCPX
| $2.18M | 0.12% | +2,445,240 | New | +$2.18M |
|
17
Arbutus Biopharma
ABUS
$711M
| $2.11M | 0.11% | 648,200 -144,417 | -18% | -$469K |
|
|
SPNC
18
DELISTED
Spectranetics Corp
SPNC
| $2.1M | 0.11% | +72,000 | New | +$2.1M |
|
19
Plus Therapeutics
PSTV
$45.3M
| $2.03M | 0.11% | 1,271,303 -380,532 | -23% | -$609K |
|
20
Editas Medicine
EDIT
$231M
| $2.02M | 0.11% | 90,300 -24,700 | -21% | -$551K |
|
|
BPMC
21
DELISTED
Blueprint Medicines
BPMC
| $2M | 0.11% | +50,000 | New | +$2M |
|
22
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $1.97M | 0.11% | 93,308 +64,690 | +226% | +$1.37M |
|
23
Intellia Therapeutics
NTLA
$1.22B
| $1.97M | 0.11% | 140,000 +10,000 | +8% | +$141K |
|
24
Ocugen
OCGN
$319M
| $1.9M | 0.1% | 1,095,422 +150,531 | +16% | +$260K |
|
25
DURECT Corp
DRRX
$59.6M
| $1.74M | 0.09% | 1,659,610 +131,094 | +9% | +$138K |
|